JP2001503028A5 - - Google Patents

Download PDF

Info

Publication number
JP2001503028A5
JP2001503028A5 JP1998513794A JP51379498A JP2001503028A5 JP 2001503028 A5 JP2001503028 A5 JP 2001503028A5 JP 1998513794 A JP1998513794 A JP 1998513794A JP 51379498 A JP51379498 A JP 51379498A JP 2001503028 A5 JP2001503028 A5 JP 2001503028A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1998513794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001503028A (ja
Filing date
Publication date
Priority claimed from US08/712,358 external-priority patent/US20020052309A1/en
Application filed filed Critical
Publication of JP2001503028A publication Critical patent/JP2001503028A/ja
Publication of JP2001503028A5 publication Critical patent/JP2001503028A5/ja
Withdrawn legal-status Critical Current

Links

JP10513794A 1996-09-11 1997-09-10 内皮損傷の治療方法 Withdrawn JP2001503028A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/712,358 US20020052309A1 (en) 1996-09-11 1996-09-11 Method of treating endothelial injury
US08/712,358 1996-09-11
PCT/US1997/015966 WO1998010650A1 (en) 1996-09-11 1997-09-10 Method of treating endothelial injury

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2008048009A Division JP2008133305A (ja) 1996-09-11 2008-02-28 内皮細胞の阻止作用を強化する薬剤
JP2009086240A Division JP2009196999A (ja) 1996-09-11 2009-03-31 内皮細胞の損傷を減らす薬剤

Publications (2)

Publication Number Publication Date
JP2001503028A JP2001503028A (ja) 2001-03-06
JP2001503028A5 true JP2001503028A5 (enExample) 2005-04-07

Family

ID=24861777

Family Applications (3)

Application Number Title Priority Date Filing Date
JP10513794A Withdrawn JP2001503028A (ja) 1996-09-11 1997-09-10 内皮損傷の治療方法
JP2008048009A Pending JP2008133305A (ja) 1996-09-11 2008-02-28 内皮細胞の阻止作用を強化する薬剤
JP2009086240A Pending JP2009196999A (ja) 1996-09-11 2009-03-31 内皮細胞の損傷を減らす薬剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2008048009A Pending JP2008133305A (ja) 1996-09-11 2008-02-28 内皮細胞の阻止作用を強化する薬剤
JP2009086240A Pending JP2009196999A (ja) 1996-09-11 2009-03-31 内皮細胞の損傷を減らす薬剤

Country Status (11)

Country Link
US (5) US20020052309A1 (enExample)
EP (1) EP0933995B8 (enExample)
JP (3) JP2001503028A (enExample)
CN (2) CN1113669C (enExample)
AT (1) ATE282425T1 (enExample)
CA (1) CA2265547C (enExample)
DE (1) DE69731652T2 (enExample)
DK (1) DK0933995T3 (enExample)
ES (1) ES2231889T3 (enExample)
PT (1) PT933995E (enExample)
WO (1) WO1998010650A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
IL124015A0 (en) 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
FR2786104B1 (fr) * 1998-11-25 2002-12-27 Centre Nat Rech Scient Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques
US7309687B1 (en) * 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
TR200103785T2 (tr) * 1999-04-13 2002-06-21 The Kenneth S. Warren Institute, Inc. Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi
US6171620B1 (en) * 1999-04-27 2001-01-09 Health Research, Inc. Method of enhancing the efficacy of anti-tumor agents
WO2000067776A1 (en) * 1999-05-11 2000-11-16 Ortho-Mcneil Pharmaceuticals, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
US20030152562A1 (en) * 2001-10-23 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Vitro micro-organs, and uses related thereto
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US20020061849A1 (en) * 2000-05-02 2002-05-23 Soren Nielsen Methods for treatment of diseases associated with inflammation under non-ischemic conditions
DE60131393D1 (de) * 2000-05-02 2007-12-27 Action Pharma As Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
EP1930023A3 (en) * 2001-04-09 2008-08-06 East Carolina University Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
US20020169128A1 (en) * 2001-04-09 2002-11-14 Geroge Sigounas Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
DK1459762T3 (da) * 2001-11-02 2008-10-06 Yoshiko Yasuda Anvendelse af EMP9 til forebyggelse af proliferative organsygdomme
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
GB0211578D0 (en) * 2002-05-21 2002-06-26 Univ Belfast Medicaments
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
CN1897959A (zh) * 2003-09-29 2007-01-17 沃伦药品公司 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子
WO2005094236A2 (en) * 2003-11-07 2005-10-13 Henry M. Jackson Foundation Activation of hypoxia-inducible gene expression
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
WO2005099773A1 (en) * 2004-04-05 2005-10-27 University Of Vermont And State Agricultural College Use of erythropoietin for treatment of cancer
US20110076255A1 (en) * 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
WO2008050836A1 (en) * 2006-10-25 2008-05-02 Ajinomoto Co., Inc. Agent for ameliorating adverse side-effect of chemotherapeutic agent
RU2426174C1 (ru) * 2010-03-29 2011-08-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ фармакологической коррекции ишемии конечности, в том числе при l-name индуцированном дефиците оксида азота
US9533010B2 (en) * 2011-10-31 2017-01-03 Amorcyte, Llc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
CN105189556A (zh) * 2013-03-15 2015-12-23 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
EP4340865A4 (en) * 2021-05-18 2025-04-02 Attias, Eyal USE OF ERYTHROPOIETIN (EPO) OR ERYTHROPOIESIS STIMULATING AGENT (ESA) FOR THE TREATMENT OF OSTEOMYELITIS, BONE INFECTION AND BONE INFLAMMATION

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
US5002755A (en) * 1988-02-18 1991-03-26 Vanderbilt University Method of controlling nephrotoxicity of anti-tumor plaintum compounds
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
JPH0782174A (ja) * 1993-09-17 1995-03-28 Takeda Chem Ind Ltd 抗腫瘍剤
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
JP2001520503A (ja) * 1994-12-30 2001-10-30 カイロン コーポレイション インビボにおける固形腫瘍の処置のための方法および組成物
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions

Similar Documents

Publication Publication Date Title
JP2001523987A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2001504721A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2000500026A5 (enExample)
JP2000502472A5 (enExample)
JP2000501338A5 (enExample)
JP2000501825A5 (enExample)
JP2000500874A5 (enExample)
JP2000515570A5 (enExample)
JP2000502425A5 (enExample)
JP2000502485A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2001501351A5 (enExample)
JP2001500441A5 (enExample)
JP2001506603A5 (enExample)
JP2000501744A5 (enExample)
JP2000512627A5 (enExample)
JP2000501229A5 (enExample)
JP2000500857A5 (enExample)